DAX24.340 +0,2%Est505.746 -0,1%MSCI World4.343 -0,1%Top 10 Crypto10,94 -5,7%Nas23.593 -0,1%Bitcoin74.297 +0,2%Euro1,1776 ±0,0%Öl60,64 -2,6%Gold4.533 +1,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Novo Nordisk A3EU6F Rheinmetall 703000 DroneShield A2DMAA Allianz 840400 Tesla A1CX3T Nike 866993 Amazon 906866 BYD A0M4W9 Bayer BAY001 Lufthansa 823212 Deutsche Telekom 555750 D-Wave Quantum A3DSV9 Alphabet A (ex Google) A14Y6F Microsoft 870747
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt vor Weihnachten etwas höher -- Alphabet kauft Intersect -- Novo Nordisk, D-Wave, Lufthansa, Palantir, TUI, Microsoft, Bitcoin, Gold im Fokus
Top News
Allianz Global Investors Ausblick 2026: Welche Regionen sich für Aktienanleger lohnen Allianz Global Investors Ausblick 2026: Welche Regionen sich für Aktienanleger lohnen
KW 52: So haben Bitcoin, Ether & Co. in der vergangenen Woche performt KW 52: So haben Bitcoin, Ether & Co. in der vergangenen Woche performt
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Cumberland Pharmaceuticals Aktie

Kaufen
Verkaufen
4,08 USD -0,10 USD -2,39 %
nachbörslich
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.53,34 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0RC46

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS2307701092

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCPIX

Cumberland Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireCALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT
PR NewswireCUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH
PR NewswireCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE
PR NewswireCUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
PR NewswireCUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.
PR NewswireCUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO
PR NewswireTABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA
PR NewswireCumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
PR NewswireCUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK
PR NewswireCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE
PR NewswireCumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
PR NewswireNEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS
PR NewswireCUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
PR NewswireCumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025
PR NewswireCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE
PR NewswireFIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
PR NewswireCumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
PR NewswireCUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
PR NewswireVIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
PR NewswireCumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
PR NewswireFDA APPROVES ACETADOTE® sNDA
PR NewswireCumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
PR NewswireCUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
PR NewswireNew Study Compares Caldolor® (ibuprofen injection) to ketorolac
PR NewswireCUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS
PR NewswireCumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024
PR NewswireCUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS
PR NewswireCumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update
PR NewswireCUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS
PR NewswireNEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS
PR NewswireCumberland Pharmaceuticals Reports Annual 2023 Financial Results
PR NewswireCUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS
PR NewswireCumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results
PR NewswireCUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS
PR NewswireNEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE
PR NewswireCumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023
PR NewswireCUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS
PR NewswireNEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS
PR NewswireCUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
PR NewswireCALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS

Cumberland Pharmaceuticals News

Cumberland Pharmaceuticals News: auf dieser Seite finden Sie alle Cumberland Pharmaceuticals News und Nachrichten zur Cumberland Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Cumberland Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Cumberland Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.